MailChimp for WordPress: Form Preview

[mc4wp_form]

Like this:

Like Loading...

THE PDMP & ITS BRANDING OF PAIN PATIENTS

Caylee Cresta: CMS FINAL CALL: RULES ON 2019 CMS OPIOID PRESCRIBING

Pain Advocacy Coalition

This slideshow requires JavaScript.

#Jams4eAdvocacy

Funky Funky Music (Free Download)

Barbatuques-Biana-ClozeeRmx-Friskie-Edit

It's Too Late (BadboE Ghetto Funk Remix)

BadboE - The Bullet Jam

Hercules '2012

#RiseUP

Pain Advocacy Coalition

© Pain Advocacy Coalition (2017- 2020) All rights reserved. Content does not constitute a medical consultation or legal advice. Please see a certified medical professional for medical advice or consult an attorney for legal advice. Content reflects the personal opinion of each individual contributor based upon available information. Unauthorized use/ duplication of content without express and written permission from content author is strictly prohibited. Excerpts or links may be used provided full clear credit is given to Pain Advocacy Coalition authors by including appropriate citation and links to the original content.

JD Supra Law

FDA Issues Long-Overdue Regulations on Direct-To-Consumer Advertisements for Prescription Medications November 30, 2023
On November 21, 2023, the FDA published its final rule changing how prescriptions medicines are advertised to consumers. The FDA first issued its proposed rule in 2010, which subsequently went through three public comment periods between 2010 and 2012. Interestingly, the FDA provided no opportunities for the public to comment on the rule since 2012.
Knobbe Martens
Holland & Knight Health Dose: November 28, 2023 November 30, 2023
Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.
Holland & Knight LLP
Delay Is Okay: Final Written Decisions Can Be Issued After Statutory Deadline November 30, 2023
In a matter of first impression, the US Court of Appeals for the Federal Circuit concluded that the Patent Trial & Appeal Board has the authority to issue a final written decision (FWD) in a post-grant review (PGR) proceeding after the statutory deadline has passed. Purdue Pharma L.P. v. Collegium Pharm., Inc., Case No. 22-1482 […]
McDermott Will & Emery